Disney Is Correct: It Is a Small World for . . . Investigating Psoriasis

Christopher Griffiths, Head of Dermatology at the University of Manchester in the UK gave the plenary Eugene Farber lecture on “The Natural History of Psoriasis” at the Society for Investigative Dermatology annual meeting on May 7, 2015 in Atlanta, Georgia. I was stimulated in many dimensions:  by the excellent research and presentation style, the wonderful use of the King’s/Queen’s English, and the incredible organization of the UK Dermatology enterprise in generating and sharing data.

The English dermatologists have developed nationwide organizations for collecting, analyzing, and disseminating important clinical data. A little investigation showed that dermatologists around the world are contributing to similar big data sets for the benefit of patients.

Examples are within an alphabet soup of acronyms; it should be noted that the BAD, the British Association of Dermatologists, is a key mover in this process. UK-TREND (UK Translational Research Network in Dermatology), a membership organization started in 2013, is one example of the BAD’s commitment to facilitating translational research in skin biology and disease to improve patient care.-

 

image credit: www.shutterstock.com / 903418000Other examples include:

BADBIR – British Association of Dermatologists Biologic Interventions Register

BADGEM – British Association of Dermatologists Dermatology and Genetic Medicine

PSORT –  Psoriasis stratification to optimize relevant therapy

 

Another international group collecting data, including data on adverse events is:

PSOLAR – (Psoriasis Longitudinal Assessment and Registry) is a multinational group of investigators collecting important data on longitudinal fashion on now over 1,496 patients (Kalb et al, 2015) in the US (74.3%), Canada (13.7%), and the rest in other regions of the world.

 

All of these groups address important research and clinical issues, and several have industry support.

Data from these groups will lead to relevant information for patient management.. The stratification studies can also lead to choosing between apparently equivalent therapies that may be more beneficial for one subset of patients compared with others.

 

REFERENCE:

RE Kalb, DF Fiorentino, MG Lebwohl, et al (2015) Risk of serious infection with biologic and systemic treatment for psoriasis. JAMA Dermatology   doi: 10.1001/jamaddermatol.2015.0718

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s